No Data
No Data
Olema Pharmaceuticals: Promising Clinical Results and Strong Financial Health Support Buy Rating
Oppenheimer Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Olema Pharmaceuticals (OLMA) Receives a Buy From Oppenheimer
Olema Pharmaceuticals Analyst Ratings
Olema Pharmaceuticals Unveils Strategic Priorities and Pipeline
Olema Pharmaceuticals Grants Stock Options to New Employees and Chief Legal Officer